|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
EP0382781B1
(en)
|
1987-10-23 |
1993-09-29 |
Genetics Institute, Inc. |
Composition for treating cancers characterized by over-expression of the c-fms proto-oncogene
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
DE69329247T2
(de)
|
1992-06-09 |
2001-05-31 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Kristallisierung von m-csf
|
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
|
JPH10218791A
(ja)
|
1997-01-31 |
1998-08-18 |
Toagosei Co Ltd |
慢性関節リウマチ治療薬
|
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
WO1999029345A1
(en)
|
1997-12-05 |
1999-06-17 |
La Jolla Institute For Experimental Medicine |
Inhibition of tumor growth by macrophage intervention
|
|
CA2348292A1
(en)
|
1998-10-30 |
2000-05-11 |
Takeda Chemical Industries, Ltd. |
Betacellulin protein-containing preparation
|
|
BR0011197A
(pt)
|
1999-05-07 |
2002-02-19 |
Genentech Inc |
Método de tratamento de uma doença autoimunológica em um mamìfero, compreendendo antagonistas que se ligam aos marcadores de superfìcie de células b e artigo de manufatura
|
|
CA2388298C
(en)
|
1999-10-28 |
2013-05-14 |
Seyedhossein Aharinejad |
The use of csf-1 inhibitors
|
|
WO2001034177A2
(en)
|
1999-11-08 |
2001-05-17 |
The Government Of The United States Of America, A S Represented By The Secretary, Department Of Hea Lth & Human Services, The National Institutes Of Health |
Method of treating a viral infection using antagonists of macrophage colony stimulating factor
|
|
US7108852B2
(en)
|
2000-03-20 |
2006-09-19 |
Warner-Lambert Company Llc |
Methods of treating inflammation using antibodies to M-CSF
|
|
US7455836B2
(en)
|
2000-05-08 |
2008-11-25 |
The University Of Melbourne |
Method of treatment and agents useful for same
|
|
US6773895B2
(en)
|
2000-09-01 |
2004-08-10 |
Boehringer Ingelheim Pharma Kg |
Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
|
|
US7247618B2
(en)
|
2001-04-30 |
2007-07-24 |
Tripathi Rajavashisth |
Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
|
|
EP1423428B2
(en)
|
2001-06-20 |
2012-11-14 |
Fibron Ltd. |
Antibodies that block fgfr3 activation, methods of screening for and uses thereof
|
|
EP2246363A1
(en)
|
2002-11-15 |
2010-11-03 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
|
PL1678314T3
(pl)
|
2003-10-22 |
2013-02-28 |
Keck Graduate Inst |
Sposoby syntezy polipeptydów heteromultimerycznych w drożdżach, wykorzystujące strategię kojarzenia haploidalnego
|
|
GB0325836D0
(en)
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
|
EP1706137A2
(en)
|
2004-01-21 |
2006-10-04 |
Chiron Corporation |
M-csf muteins and uses thereof
|
|
JP2008506366A
(ja)
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
AU2005267062C1
(en)
|
2004-07-22 |
2013-01-17 |
Five Prime Therapeutics, Inc. |
Compositions and methods of use for MGD-CSF in disease treatment
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
AU2006207999A1
(en)
|
2005-01-27 |
2006-08-03 |
Five Prime Therapeutics, Inc. |
Leader sequences for directing secretion of polypeptides and methods for production thereof
|
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
|
BRPI0618449A2
(pt)
|
2005-11-10 |
2011-08-30 |
Receptor Biologix Inc |
métodos para produção de isoformas de receptor e ligante
|
|
WO2007075933A2
(en)
|
2005-12-21 |
2007-07-05 |
Cell Signaling Technology, Inc. |
Translocation and mutant csf1r kinase in human leukemia
|
|
AU2006342119B8
(en)
|
2005-12-22 |
2013-05-09 |
Novartis Ag |
Soluble human M-CSF receptor and uses thereof
|
|
CN101534858A
(zh)
|
2006-01-05 |
2009-09-16 |
诺华有限公司 |
预防和治疗癌症转移和癌症转移相关性骨丢失的方法
|
|
AU2007248493B2
(en)
|
2006-05-04 |
2010-09-30 |
The Rockefeller University |
HCV coreceptor and methods of use thereof
|
|
US7833789B2
(en)
|
2006-08-01 |
2010-11-16 |
Fondazione Centro San Raffaele Del Monte Tabor |
Monocyte cell
|
|
EP2089049A4
(en)
|
2006-11-17 |
2011-11-16 |
Biogen Idec Inc |
SYSTEMIC ADMINISTRATION OF COLONIAL STIMULATING FACTORS TO TREAT AMYLOID ASSOCIATED DISEASES
|
|
ATE494306T1
(de)
|
2007-02-14 |
2011-01-15 |
Vaccinex Inc |
Humanisierte anti-cd100-antikörper
|
|
WO2008124858A2
(en)
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
WO2008150383A1
(en)
|
2007-05-30 |
2008-12-11 |
Albert Einstein College Of Medicine Of Yeshiva University |
Csf-1r mutants
|
|
SG10201500328QA
(en)
|
2007-08-21 |
2015-03-30 |
Amgen Inc |
Human c-fms antigen binding proteins
|
|
US7981415B2
(en)
|
2007-09-07 |
2011-07-19 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
|
EP2215482A2
(en)
|
2007-10-31 |
2010-08-11 |
Janssen Pharmaceutica N.V. |
Biomarker for assessing response to fms treatment
|
|
JPWO2009075344A1
(ja)
|
2007-12-12 |
2011-04-28 |
独立行政法人国立がん研究センター |
Ｍ−ｃｓｆ受容体を分子標的とするｍｌｌ白血病及びｍｏｚ白血病治療剤、およびその利用
|
|
WO2009112245A1
(en)
|
2008-03-14 |
2009-09-17 |
Transgene S.A. |
Antibody against the csf-1 r
|
|
US8470977B2
(en)
|
2008-03-14 |
2013-06-25 |
Transgene S.A. |
Antibody against the CSF-1R
|
|
US8183207B2
(en)
|
2008-11-26 |
2012-05-22 |
Five Prime Therapeutics, Inc. |
Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
|
|
US8080246B2
(en)
|
2008-11-26 |
2011-12-20 |
Five Prime Therapeutics, Inc. |
Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
|
|
CN105218672A
(zh)
|
2009-12-10 |
2016-01-06 |
霍夫曼-拉罗奇有限公司 |
优先结合人csf1r胞外域4的抗体及其用途
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
RU2617966C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
KR20200044999A
(ko)
*
|
2010-05-04 |
2020-04-29 |
파이브 프라임 테라퓨틱스, 인크. |
Ｃｓｆ1ｒ에 결합하는 항체들
|
|
WO2012082573A1
(en)
|
2010-12-13 |
2012-06-21 |
Novartis Ag |
Predictive methods and methods of treating arthritis using il-17 antagonists
|
|
US20140288279A1
(en)
|
2011-10-21 |
2014-09-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
M-DC8+ Monocyte Depleting Agent for the Prevention or the Treatment of a Condition Associated with a Chronic Hyperactivation of the Immune System
|
|
US9139652B2
(en)
|
2011-10-21 |
2015-09-22 |
Transgene Sa |
Method for increasing M1 macrophages in a patient
|
|
EP2847220A1
(en)
*
|
2012-05-11 |
2015-03-18 |
Five Prime Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
TWI713436B
(zh)
*
|
2012-08-31 |
2020-12-21 |
美商戊瑞治療有限公司 |
用結合群落刺激因子１受體（ｃｓｆ１ｒ）之抗體治療病狀之方法
|
|
PL3212670T3
(pl)
*
|
2014-10-29 |
2021-06-14 |
Five Prime Therapeutics, Inc. |
Leczenie skojarzone nowotworów
|